News Headlines Article

Opposition sidelines bill to sunshine high drug costs
Sacramento Business Journal

Opposition from drug companies and tech groups has sidelined legislation to sunshine production costs of expensive specialty drugs, while legislation to cap the amount consumers pay for these medications moved ahead.

Assemblyman David Chiu announced plans this week to pull back Assembly Bill 463 for now, but make another go at it next year. The bill would require drug manufacturers to report research and development costs and subsidies, pricing history, acquisition costs and profits attributable to drugs or treatments priced at or above $10,000.